ecancer interviewed ISA’s Chief Science Officer Prof. Dr. Kees Melief on his views on cancer vaccines during the AACR annual meeting 2019 in Atlanta.

Prof. Melief discusses the favourability of cancer vaccines. Cancer vaccines can be easily applied to large numbers of patients and are low in cost. When combined with chemotherapy and immunotherapy they can have great benefit.

He also speaks about ISA’s latest study looking at the HPV-specific T-cell response after chemo-immunotherapy for advanced cervical cancer.

In Atlanta Prof. Melief received the AACR-CRI Lloyd J. Old Award in Cancer Immunology 2019.

Link to the interview.